Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6020 in Relapsing/Refractory Multiple Sclerosis
NCT07756268Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Sep 2026
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SYS6020 in multiple sclerosis (MS), sponsored by Tongji Hospital. Primary endpoint: Safety and tolerability at Month 24. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SYS6020
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07756268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756268.